{"id":"W2977571468","doi":"10.1016/j.annonc.2019.12.006","title":"Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Surgical Treatments","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"ca_institutions":"William Osler Health System; Brampton Civic Hospital","funders":"Cilag; Genentech; Servier; Eisai; Ipsen; BeiGene; Baxalta; Array BioPharma; Halozyme; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; Novartis Farmacéutica; Celgene; Symphogen; AstraZeneca; Eli Lilly and Company; F. Hoffmann-La Roche; Chugai Pharmaceutical; Roche","keywords":"Bevacizumab; Medicine; Oxaliplatin; Internal medicine; Interquartile range; Colorectal cancer; Hazard ratio; Fluorouracil; Chemotherapy; Gastroenterology; Surgery; Oncology; Confidence interval; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004001186,0.0008117623,0.002708943,0.0006580791,0.0001972366,0.001645603,0.0006699552,0.0007088735,0.00132364],"category_scores_gemma":[0.003985549,0.0002820163,0.002557437,0.001170879,0.0003176323,0.0008580001,0.0004000518,0.00203966,0.0002815567],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00105215,"about_ca_system_score_gemma":0.001343277,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002365037,"about_ca_topic_score_gemma":0.01027787,"domain_scores_codex":[0.9991329,0.0004019507,0.00007870934,0.0001084995,0.0001839303,0.0000939777],"domain_scores_gemma":[0.9976768,0.0009433412,0.0007145338,0.0001175333,0.0002784384,0.0002693832],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2075197,0.002277041,0.02750191,0.008783794,0.01824389,0.0002008193,0.0002134929,0.005142935,0.00759284,0.0006972447,0.03460696,0.6872194],"study_design_scores_gemma":[0.3752891,0.09513728,0.2566574,0.005943049,0.08143339,0.001524208,0.0003586675,0.005337577,0.006129976,0.003377628,0.1684958,0.0003158535],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5271761,0.4401578,0.002387979,0.006810614,0.002549923,0.0009453093,0.01032331,0.0002062453,0.009442678],"genre_scores_gemma":[0.7712856,0.1828658,0.006091716,0.01021692,0.001941868,0.00100948,0.02174609,0.0002234463,0.004619029],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004001186,"threshold_uncertainty_score":0.02116054,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1335172886597523,"score_gpt":0.4333137783944712,"score_spread":0.299796489734719,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}